Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Insider Sells $21,204.48 in Stock

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) insider Ronald Silver sold 12,048 shares of the business's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $1.76, for a total value of $21,204.48. Following the completion of the transaction, the insider now owns 279,655 shares in the company, valued at approximately $492,192.80. This trade represents a 4.13 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Ironwood Pharmaceuticals Stock Down 4.5 %

IRWD traded down $0.09 during midday trading on Friday, hitting $1.92. The company had a trading volume of 2,151,349 shares, compared to its average volume of 2,572,680. The company has a market capitalization of $307.26 million, a price-to-earnings ratio of -64.00 and a beta of 0.29. Ironwood Pharmaceuticals, Inc. has a 52 week low of $1.59 and a 52 week high of $15.65. The stock's 50 day moving average price is $3.54 and its 200 day moving average price is $4.10.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. KBC Group NV increased its stake in Ironwood Pharmaceuticals by 59.3% during the 3rd quarter. KBC Group NV now owns 8,593 shares of the biotechnology company's stock valued at $35,000 after purchasing an additional 3,198 shares in the last quarter. Journey Strategic Wealth LLC purchased a new position in Ironwood Pharmaceuticals during the fourth quarter valued at approximately $45,000. Catalyst Funds Management Pty Ltd purchased a new position in Ironwood Pharmaceuticals during the fourth quarter valued at approximately $47,000. Xponance Inc. bought a new stake in shares of Ironwood Pharmaceuticals during the fourth quarter valued at approximately $50,000. Finally, Envestnet Asset Management Inc. bought a new stake in shares of Ironwood Pharmaceuticals during the fourth quarter valued at approximately $50,000.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on IRWD shares. Craig Hallum lowered their target price on shares of Ironwood Pharmaceuticals from $10.00 to $8.00 and set a "buy" rating on the stock in a research report on Wednesday, January 22nd. StockNews.com cut shares of Ironwood Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, November 12th. Finally, JMP Securities dropped their price objective on shares of Ironwood Pharmaceuticals from $23.00 to $14.00 and set a "market outperform" rating for the company in a research report on Thursday, January 30th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $10.67.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.